Kyntra Bio, Inc. (0IL8)

Overview

FibroGen, Inc. is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to address significant unmet medical needs. Since its establishment in 1993, the company has dedicated its efforts to advancing science and medicine in areas where they can make a substantial difference. With a head office located in San Francisco, California, FibroGen is at the forefront of biotechnological innovation, guided by collaboration agreements with global leaders like Astellas Pharma Inc. and AstraZeneca AB. This strategic positioning allows FibroGen to not only develop but also potentially deliver game-changing treatments on a worldwide scale.

Products and Services

• Pamrevlumab

  A forefront innovation by FibroGen, Pamrevlumab, is a human monoclonal antibody that targets the connective tissue growth factor (CTGF). It is currently in Phase III clinical development for patients with locally advanced pancreatic cancer. By focusing on CTGF, Pamrevlumab aims to offer a novel treatment pathway for this challenging disease, potentially improving the survival and quality of life for patients facing pancreatic cancer.

• Roxadustat

  This oral small molecule inhibitor marks a significant breakthrough in the treatment of anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). By inhibiting hypoxia-inducible factor prolyl hydroxylase activity, Roxadustat addresses anemia by mimicking the body’s response to high altitudes, thus promoting red blood cell production. Successfully completing Phase III clinical development in various regions including China, Europe, and Japan, Roxadustat stands out as a critical advancement in managing CKD and MDS-related anemia.